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ABSTRACT
The Ontario Cancer Research Ethics Board (OCREB)
has made its mark within Ontario as a successful,
centralized, oncology-specific research ethics board.
As such, OCREB has proven invaluable to principal
investigators, sponsors, and study participants given
its ability to reduce duplication during the submis-
sion process, to provide the highest quality of re-
view, to shorten study start-up time, and to implement
more efficient methods of reporting serious adverse
events.
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1. INTRODUCTION
The seed from which the Ontario Cancer Research
Ethics Board (OCREB) sprang was planted in 2001. At
the time, Raphael Saginur, an Ottawa-based clinical
scientist and research ethics board (REB) chair, together
with the Ontario Cancer Research Network, recog-
nized the growing need to improve and streamline
scientific and ethical reviews of multicentre cancer
trials. They were not alone in their assessment; many
other groups around the world were also experiment-
ing with coordinated REB reviews, and precedents for
centralized REBs did exist, meeting with mixed
success 1,a.
Nurturing the idea took two years of thorough
consultations among REB chairs, cancer centres, hos-
pitals, researchers, bioethicists, clinical research co-
ordinators, sponsors, and many collaborating centres
(Table I). Those dialogues identified key issues that
still apply today and that buttress support for the cre-
ation of a centralized, oncology-specific REB.
The major challenges faced by all ethics boards
are the growing volume of clinical trials and the in-
creasingly complex regulations governing REBs. Cop-
ing with the resulting increase in workload to review,
approve, and monitor clinical trials is a significant
burden. The REBs must find and retain appropriately
qualified members, secure adequate resources and
office staff, and respond to investigators in a timely
fashion. Ensuring consistency of reviews across REBs
is also an issue for multicentre studies. Such firmly
rooted needs propelled the decision to move OCREB
forward.
The organization’s framework took shape very
quickly, with the chair, vice-chair, and fourteen REB
members being recruited within four to five months.
Under the aegis of a provincial program promoting
clinical research, OCREB was officially launched in
December 2003. At that time, OCREB’s funding flowed
from the Ontario Cancer Research Network, whose
programs were subsequently incorporated into the
Ontario Institute for Cancer Research (OICR) in 2005.
Currently,  OCREB is funded at arm’s length by OICR
and is independent of both the researchers conduct-
ing the clinical trials and the organizations sponsor-
ing the research. It is accountable to an Advisory
Committee that liaises with OICR’s board of directors.
2. ROLE OF OCREB
To appreciate the unique position that OCREB occupies
in cancer clinical trials in Ontario, a review of the spon-
sor–investigator–REB relationship is worthwhile.
Sponsors typically develop and fund a study, co-
ordinate the regulatory submissions (for example, to
Health Canada), select the sites (often globally),
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TABLE I Centres collaborating to form the Ontario Cancer Research
Ethics Board
Cancer Care Ontario
National Council for Ethics in Human Research
Canadian Association of Research Ethics Boards
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monitor study progress, and manage the data analy-
sis and study reporting. Many studies are sponsored
by pharmaceutical or biotechnology companies that
develop the therapies being evaluated. Cooperative
groups such as the Clinical Trials Group of the Na-
tional Cancer Institute of Canada also sponsor stud-
ies and run them through multiple sites established
across the country. As well, the Princess Margaret
Hospital (PMH) Phase II Consortium sponsors studies
that are conducted at four major cancer centres in
Ontario, including PMH, and at centres in British Co-
lumbia, Alberta, and the United States. Investigators
may also serve as sponsors.
Regardless of sponsorship, every site participat-
ing in a multicentre trial must gain approval from a
REB. That process is set in motion by the principal
investigator (PI) at each site. The PI submits the study
protocol and supporting documents to the local insti-
tutional REB. The REB reviews and may request clari-
fications or changes to the protocol and consent form
before granting approval to run the trial.
The site PI is also responsible for the conduct of
the trial at the site, including follow-up and reporting
of all medical incidents, termed adverse events (AEs),
to the sponsor and the REB. Serious AEs (SAEs) war-
rant special scrutiny and must be reported in timely
fashion. The REB is accountable to the institution for
initial and ongoing ethical review and oversight of
the research, a process that may result in disapproval,
modifications to approved research, temporary shut-
downs, or termination of the research project if
deemed necessary.
As with any REB, OCREB is charged with the task of
protecting volunteers who participate in clinical trials
by ensuring respect for human dignity, free and in-
formed consent, privacy and confidentiality, justice
and inclusiveness, and balance in the harms and ben-
efits of treatments. The qualities that distinguish OCREB
from existing REBs stem from a versatile combination
of its centralization, specialization, and management.
Centralization allows OCREB to serve as the REB
for multiple institutions and reduces duplication dur-
ing the submission process. For example, in a
multicentre trial in which three sites retain OCREB, only
one site investigator, deemed the “provincial appli-
cant,” is required to embark on the full submission
process on behalf of the province. Upon OCREB grant-
ing provincial approval, the sites are either approved
in parallel if their abbreviated centre-specific appli-
cations are received at the same time as the provin-
cial application, or are given expedited approval if
they submit at a later date. Additional centres can
easily join the study at any point during the process,
and all participating centres agree to use the same
consent form unless institutional policy requires spe-
cific local changes. Thus OCREB lessens the workload
for the submitters and not only expedites but also
coordinates the study start-up at multiple sites across
the province. Centralization also permits safety is-
sues to be addressed simultaneously, given that safety
updates and amendments to the protocol and consent
form apply equally at each site.
The benefits of centralization synergize with
OCREB’s specialization in oncology. The board com-
prises seventeen members with a broad range of ex-
pertise in oncology, clinical research, biostatistics,
epidemiology, pharmacology, research ethics, law,
privacy, and community issues. This group offers
applicants the highest quality of review and oversight.
With greater knowledge and expertise in cancer than
institutions with more generalized REBs, OCREB can
provide a better context in which to oversee trials in
specialized areas of oncology.
Underpinning the foregoing distinguishing quali-
ties is OCREB’s strategic management, developed under
the expert leadership of the executive director, Janet
Manzo, and with guidance from the chair of OCREB,
Dr. Ron Heslegrave, and the chair of OCREB’s Advi-
sory Committee, Dr. Raphael Saginur. Together with
OCREB’s staff, these individuals have worked to pre-
serve a level of internal flexibility that has allowed
the organization to refine its operational strategies as
it gained experience. Paramount to OCREB’s success
has been its ability to foster collaboration within the
research ethics community through communication,
exchange of information, and promotion of change.
In theory, the combination of all its assets should
place OCREB in the sought-after position of being able
to streamline the work of PIs, participating centres,
and institutional REBs. In practice, OCREB is living up
to that potential. In OCREB’s first year of operation,
institutions retained it either for a “facilitated review”
or as their REB “of record.” For the former option,
OCREB provides an expert review of the study to as-
sist the local REB, which remains responsible for the
study within the institution. For the latter option,
OCREB enters into a contract with the institution to act
as its REB on a study-by-study basis for initial and
ongoing review.
In 2004, five sites used OCREB as their REB of record,
and OCREB received 19 multicentre cancer protocols 2.
At the end of 2005, the number of institutions using
OCREB had increased to seven, and the number of new
submissions, to 31. By the end of 2006, the number of
institutions authorizing a formal REB-of-record rela-
tionship with OCREB had doubled to fourteen, and 56
new submissions had been received. Today, OCREB is
being used solely as a REB of record, and by August
2007, it had reviewed another 42 multicentre cancer
protocols (Figure 1). Table II lists the centres that have
authorized their institutions to use OCREB as REB of
record on a study-by-study basis.
3. PROOF OF CONCEPT
The proof of OCREB’s success lies not only in the in-
crease in submissions to the board, but also in the
testimonies of users and in their assessments ofCHADDAH
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OCREB’s ability to deal with the challenges faced by
the burgeoning organization.
Dr. Amit Oza, one of the three PIs with the PMH
Phase II Consortium group, attests to the fact that
OCREB has achieved the difficult task of securing the
trust of local institutional REBs and of PIs. Princess
Margaret Hospital has the distinction of being the first
centre to use OCREB, initially for facilitated review but
later as REB of record for PMH Phase II Consortium
trials, and the Consortium is therefore well positioned
to assess OCREB’s progress. “Local institutional review
boards take the responsibility to their institution very
seriously, so handing off that responsibility to OCREB
was a very big leap of faith,” says Oza.
Although OCREB was rapidly adopted by non-
academic hospitals with limited expertise in cancer-
specific research ethics, larger academic hospitals
were slower to follow suit. Some even made the sig-
nificant investment of testing the waters by estab-
lishing parallel submission for a time to assess how
OCREB would fare. In doing so, they learned that OCREB
had the capacity to shave three weeks off trial start-
up time (Figure 2).
In Oza’s opinion, OCREB “met the challenge of
building up its resources over time, and is now more
efficient than any other REB.” He views OCREB’s great-
est strengths as “streamlining the administrative pro-
cess through multiple sites, getting trials opened at
sites simultaneously, and the quality of its reviews.”
Connie Dupuis, country study manager at
Hoffmann–La Roche, is also an advocate of OCREB.
She sees the organization as having “demonstrated
its commitment to a centralized research ethics re-
view board function in Ontario. The single review
on behalf of several centres has the potential to be
more efficient than several individual submissions and
reviews in terms of time and resources, and has the
potential to shorten study start-up timelines and sup-
port clinical trials completion.”
Academic investigators and industry sponsors
alike are encouraged that OCREB has developed a work-
able solution to the challenge of reporting SAEs. Seri-
ous and unexpected AEs are reported by the sponsors
to regulatory agencies such as Health Canada and to
every researcher testing the same drug in any study.
These reports—termed “external SAEs”—flood in
from around the world. Before submitting these ex-
ternal SAE reports to their REB, trial investigators must
photocopy the multiple pages of each report and then
create, complete, and sign a summary form indicat-
ing that they have reviewed the documents.
TABLE II Institutions using the Ontario Cancer Research Ethics
Board
Trillium Health Centre (Mississauga)
Thunder Bay Regional Health Sciences Centre Cancer Care
Program
Southlake Regional Health Centre (Newmarket)
Windsor Regional Cancer Centre
Toronto East General Hospital
Princess Margaret Hospital (Toronto)
Juravinski Cancer Centre (Hamilton)
Grand River Regional Cancer Centre (Kitchener)
Cambridge Memorial Hospital
Odette Cancer Centre a (Toronto)
Mount Sinai Hospital (Toronto)
Ottawa Hospital Regional Cancer Centre
Niagara Health Sciences (St. Catherines)
London Regional Cancer Program
a Formerly Sunnybrook Regional Cancer Centre.
FIGURE 1 Number of multicentre cancer protocols submitted
annually. Adapted, with permission, from Ontario Cancer Research
Ethics Board: 2006 Annual Report 2.
FIGURE 2 Time to research ethics board (REB) approval.OCREB: A CENTRAL REB THAT WORKS
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Dozens of SAE reports per study may arrive every
month, with the investigator often receiving the same
report for multiple studies that include the same in-
vestigational agent. The investigator and the REB can
both soon become afloat in a sea of SAEs. Although
SAEs are universally recognized as occupying a place
of central importance in protecting patient safety, the
cumbersome process of reporting them is considered
by all concerned to be the bane of clinical trials.
The simple, yet clever, approach designed by
OCREB to balance patient safety with the redundancy
of SAE reporting is to
• move toward electronic submission of SAEs (pre-
viously reported by hard copy).
• request that the sponsor submit the collated SAEs
directly to OCREB with the acknowledgment that
the site investigators must continue to receive and
review them.
• provide investigators with access to a summary
of the reported SAEs for each investigational agent.
Hoffmann–La Roche agreed to OCREB’s request
and is now using an automated electronic system to
send collated SAEs simultaneously to OCREB and site
investigators. Dupuis says that the company is “very
pleased to do this, because it substantially reduces
time and resources for both the centres and our clini-
cal monitors.” Oza sees the potential for OCREB to re-
duce the burden at individual sites and to effectively
manage the volume of SAEs.
4. SUMMARY
The critical role played by REBs cannot be overstated:
without them, clinical trials would grind to a halt.
Currently, 1335 oncology clinical trials are under-
way in Canada, 430 of them in Ontario 3,4. Of the
430, some 80% are multicentre cancer trials. The
bright future for OCREB within the vast landscape of
such trials rests in having the people, policies, and
procedures in place to streamline the submission and
ongoing review processes, while maintaining the
highest level of human participant protection. The
ability of OCREB to shorten and coordinate study start-
up times imparts a competitive edge to Ontario, not
only making the province an attractive location in
which to conduct cancer clinical trials, but also im-
proving access to novel therapies for patients with
limited treatment alternatives.
In Ontario, OCREB is poised for the substantial
growth required to oversee the ever increasing num-
ber of cancer clinical trials. Throughout Canada,
OCREB is being embraced as a viable model for pro-
vincial REBs, primarily because it is viewed as a “cen-
tral-REB model that works.”
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